Generated by AI
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing intracellular therapeutics that are designed to reach targets inside cells that have traditionally been difficult to address. Its proprietary Endosomal Escape Vehicle platform supports the delivery of genetic medicine candidates and other therapeutic modalities across multiple tissues, with a current emphasis on neuromuscular and inherited retinal diseases. The company’s pipeline includes programs in development for rare and severe conditions, reflecting its role in advancing novel drug-delivery approaches in biotechnology. Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts, and operates as a development-stage company centered on research, clinical development, and platform-driven innovation in precision medicine.
WebsiteOne Design Center Place
Boston, MA, 02210
United States
The latest articles about TRDA.
A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth Linea Aspesi Linea Aspesi BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Ex
TRDA stock fell over 15% after Entrada Therapeutics announced initial Phase 1/2 ELEVATE-45-201 study results for ENTR-601-45.
Summary of May 7's posts. Generated by AI.
No summary yet.
Summary of Jun 24's posts. Generated by AI.
Summary of Nov 22's posts. Generated by AI.
Investors talking about TRDA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.